New diabetes pill enters human testing phase

NCT ID NCT07234864

Recruiting now Disease control Sponsor: Eilean Therapeutics Source: ClinicalTrials.gov ↗

Summary

This early-stage study is testing the safety and effects of a new oral medication called ZE63-0302 in people with type 2 diabetes. Researchers will enroll 60 adults who have had diabetes for at least 7 years and are already taking up to three diabetes medications (but not insulin). Participants will take either the new drug or a placebo twice daily for four weeks while researchers monitor for side effects and how the body processes the medication.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Emeritus Research Camberwell
RECRUITING

Melbourne, Victoria, 3124, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Emeritus Research Sydney
RECRUITING

Botany, New South Wales, 2019, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Momentum Clinical Research Sunshine
NOT_YET_RECRUITING

Melbourne, Victoria, 3021, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
Momentum Clinical Research Taringa
NOT_YET_RECRUITING

Brisbane, Queensland, 4068, Australia

Contact Phone: •••-•••-•••• Email: •••••@•••••
The Republican Specialized Scientific and Prectical Medical Center of Endocrinology named after Academician Yo. Kh. Turakulov
RECRUITING

Tashkent, Tashkent, 100125, Uzbekistan

Contact

Conditions

Explore the condition pages connected to this study.

TYPE 2 DIABETES